Gilead Sciences Inc. (GILD) Earns “Outperform” Rating from Robert W. Baird
Gilead Sciences Inc. (NASDAQ:GILD)‘s stock had its “outperform” rating reiterated by research analysts at Robert W. Baird in a research report issued to clients and investors on Tuesday. They currently have a $100.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $122.00. Robert W. Baird’s price target indicates a potential upside of 37.67% from the company’s previous close.
Other equities research analysts have also issued reports about the company. Piper Jaffray Cos. set a $108.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Sunday, August 21st. Jefferies Group reiterated a “hold” rating and issued a $97.00 price objective on shares of Gilead Sciences in a research report on Friday, July 15th. Argus lowered Gilead Sciences from a “buy” rating to a “hold” rating and cut their price objective for the stock from $88.00 to $81.00 in a research report on Friday, July 29th. RBC Capital Markets reiterated an “outperform” rating and issued a $105.00 price objective (down from $120.00) on shares of Gilead Sciences in a research report on Tuesday, July 26th. Finally, Barclays PLC reiterated an “overweight” rating on shares of Gilead Sciences in a research report on Thursday, July 28th. Ten research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $102.78.
Gilead Sciences (NASDAQ:GILD) traded up 1.06% during midday trading on Tuesday, reaching $73.41. The company had a trading volume of 6,206,448 shares. Gilead Sciences has a 12-month low of $72.21 and a 12-month high of $111.11. The company has a 50-day moving average of $77.72 and a 200-day moving average of $84.20. The stock has a market capitalization of $96.88 billion, a PE ratio of 6.44 and a beta of 1.10.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/gilead-sciences-inc-gild-earns-outperform-rating-from-robert-w-baird.html
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.02 by $0.06. The firm had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The business’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same period last year, the company earned $3.15 EPS. On average, analysts predict that Gilead Sciences will post $11.76 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Investors of record on Friday, September 16th were given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.59%. The ex-dividend date was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 16.56%.
In other Gilead Sciences news, insider John C. Martin sold 100,000 shares of the business’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $80.50, for a total transaction of $8,050,000.00. Following the completion of the sale, the insider now owns 4,119,727 shares of the company’s stock, valued at $331,638,023.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kevin E. Lofton sold 3,500 shares of the business’s stock in a transaction dated Wednesday, August 24th. The shares were sold at an average price of $81.97, for a total value of $286,895.00. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in GILD. Nisa Investment Advisors L.L.C. raised its stake in Gilead Sciences by 4.3% in the first quarter. Nisa Investment Advisors L.L.C. now owns 500,421 shares of the biopharmaceutical company’s stock valued at $45,969,000 after buying an additional 20,700 shares in the last quarter. Virginia Retirement System bought a new stake in Gilead Sciences during the first quarter valued at about $45,762,000. Tiemann Investment Advisors LLC raised its stake in Gilead Sciences by 14.1% in the first quarter. Tiemann Investment Advisors LLC now owns 4,450 shares of the biopharmaceutical company’s stock valued at $409,000 after buying an additional 550 shares in the last quarter. Dynamic Advisors Solutions LLC raised its stake in Gilead Sciences by 2.1% in the first quarter. Dynamic Advisors Solutions LLC now owns 16,625 shares of the biopharmaceutical company’s stock valued at $1,527,000 after buying an additional 335 shares in the last quarter. Finally, Compton Capital Management Inc. RI raised its stake in Gilead Sciences by 0.9% in the first quarter. Compton Capital Management Inc. RI now owns 66,965 shares of the biopharmaceutical company’s stock valued at $6,151,000 after buying an additional 570 shares in the last quarter. 78.00% of the stock is owned by institutional investors and hedge funds.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.